Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.
Stanford researchers have demonstrated clinical proof of concept that a real-time biofeedback system can reduce pain and slow joint degeneration in patients with movement disorders such as knee osteoarthritis.
Stanford researchers have developed a method of reducing pulmonary hypertension (PH) in mammals by targeting FHIT (Fragile Histidine Triad), a gene not previously linked to PH but consistently reduced in blood of patients with pulmonary arterial hypertension (PAH).
Stanford scientists have developed a platform that combines Raman spectroscopy, nanomaterials, and machine learning to rapidly identify bacteria in wastewater without chemical labels.
Stanford researchers have patented a system for precise genetic modification of human embryonic stem cells (ECSs) and induced pluripotent stem cells (iPSCs).
Researchers at Stanford and WashU developed cannabinoid receptor agonists with distribution mainly to peripheral tissues. Cannabinoid agonists are relevant for treatment of many indications, but current clinical use is limited by a variety of side effects.
Aging-associated mitochondrial dysfunction (mito-dysfunction) affects every cell system in our body. Mito-dysfunction includes reduced quality of mitochondrial DNA (mtDNA), irregular generation of reactive oxygen species, and membrane potential.
In light of the opioid epidemic within the United States, Dr. Eric Gross and colleagues developed a non-opioid therapeutic that reduces pain (Stanford Medicine Press Release).
Stanford researchers in the KC Huang Lab have patented a method that identifies functionally conserved protein regions with recurrent genomic alterations in cohort studies using natural variations in genomic sequences, which allows for the discovery and further understanding o
Stanford researchers have developed novel ENPP1 and ENPP3 inhibitors for cancer immunotherapy. ENPP1 inhibitors have previously been reported but ENPP3 is a newly discovered target.
Stanford scientists in Lacramioara Bintu's lab have developed a high-throughput system to identify regulatory domains in human RNA-binding proteins, presenting a new set of tools that could greatly enhance control over gene regulation at the RNA level for therapeutic and synth
Stanford scientists have developed a gene integration system that uses human-derived helicases paired with CRISPR technology to enable precise insertion of long DNA sequences at targeted genomic locations.
Mice heterozygous for the targeted allele are viable and fertile. This polyubiquitin B (Ubb) mutation is characterized by a GFP-puror fusion protein "knock-in" allele that also abolishes endogenous gene function.